Extended Newborn Bloodspot Screening: An Update for the General Paediatrician
Authors:
- 16 November 2026
- journal article
- Published by Wiley in Journal of Paediatrics and Child Health
Abstract
Key Points: NBS for PKU and CH are cost‐effective programmes for preventing intellectual disability. NBS enables the detection of presymptomatic newborns with treatable conditions to reduce morbidity and mortality. The addition of further conditions to NBS needs to balance cost‐effectiveness, resource availability and ethical considerations.This publication has 30 references indexed in Scilit:
- Comparative analysis of gene and disease selection in genomic newborn screening studiesJournal of Inherited Metabolic Disease, 2024
- Should all children with cystic fibrosis who have responsive CFTR mutations be prescribed CFTR modulators?Journal of Cystic Fibrosis, 2023
- Fibrosis quística: epidemiología, clínica, diagnóstico y tratamientoMedicina Clinica, 2023
- Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of theNURTUREstudyMuscle & Nerve, 2023
- Principles of Genomic Newborn Screening ProgramsJAMA Network Open, 2021
- Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United StatesJAMA, 2014
- Cost-effectiveness of carrier screening for cystic fibrosis in AustraliaJournal of Cystic Fibrosis, 2012
- The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: Clinical presentation and outcomeThe Journal of Pediatrics, 2006
- Near-miss apparent SIDS from adrenal crisisThe Journal of Pediatrics, 2004
- Medium‐chain acyl CoA dehydrogenase deficiency: Its relationship to SIDS and the impact on genetic counselingJournal of Genetic Counseling, 1993